NYSEARCA:BBC Virtus LifeSci Biotech Clinical Trials ETF (BBC) Price, Holdings, & News → $5,000 Gold? (From Stansberry Research) (Ad) Free BBC Stock Alerts $27.27 +0.18 (+0.66%) (As of 05/2/2024 ET) Add Compare Share Share Today's Range$27.18▼$27.3350-Day Range$24.70▼$31.3552-Week Range$16.88▼$31.99Volume1,015 shsAverage Volume3,627 shsMarket Capitalization$10.91 millionAssets Under Management$10.83 millionDividend Yield0.32%Net Expense Ratio0.79% Stock AnalysisStock AnalysisChartHoldingsRatingsStock AnalysisChartHoldingsRatings Get Virtus LifeSci Biotech Clinical Trials ETF alerts: Email Address About Virtus LifeSci Biotech Clinical Trials ETF (NYSEARCA:BBC)The Virtus LifeSci Biotech Clinical Trials ETF (BBC) is an exchange-traded fund that mostly invests in health care equity. The fund tracks an equally weighted index of US-listed biotech companies with lead drugs in various phases of clinical trials. BBC was launched on Dec 16, 2014 and is managed by Virtus.Read More BBC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BBC ETF News HeadlinesSeptember 26, 2023 | bbc.co.ukSkipton hotel boss cleared as death crash trial collapsesJuly 30, 2023 | bbc.co.ukPuberty blockers to be given only in clinical researchMay 2, 2024 | Stansberry Research (Ad)$5,000 Gold?Former Wall Street Banker Reveals Mysterious Gold Leverage As gold continues to soar, this ex-Goldman Sachs VP says DON'T buy bullion or mining stocks. Instead, he's just shared a "gold bank" that uses about $10 of your money to harness the power of two ounces of pure gold (worth about $4,200 right now).June 29, 2023 | ft.comBiotech begins human trials of drug designed by artificial intelligenceMay 8, 2023 | finance.yahoo.com4 Best-Performing ETF Areas of Last WeekApril 2, 2023 | finance.yahoo.comBiotech Stocks Languish After Dismal Quarter of Clinical ResultsMarch 29, 2023 | bbc.comGwyneth Paltrow ski crash trial: Who's whoFebruary 23, 2023 | cbsnews.comClinical trial helping stroke victims regain functionsMay 2, 2024 | Stansberry Research (Ad)$5,000 Gold?Former Wall Street Banker Reveals Mysterious Gold Leverage As gold continues to soar, this ex-Goldman Sachs VP says DON'T buy bullion or mining stocks. Instead, he's just shared a "gold bank" that uses about $10 of your money to harness the power of two ounces of pure gold (worth about $4,200 right now).January 25, 2023 | bizjournals.comRockville biotech RegenxBio launches clinical trial in muscular dystrophySee More Headlines Receive BBC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Virtus LifeSci Biotech Clinical Trials ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address Fund Details IssuerVirtus Fund NameVirtus LifeSci Biotech Clinical Trials ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:BBC Inception Date12/16/2014 Fund ManagerMatthew B. Brown, Seth Kadushin WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkLifeSci Biotechnology Clinical Trials Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings106 Fund Statistics Assets Under Management$10.83 million Average Daily Volume$2,808.80 Discount/Premium0.01% Administrator, Advisor and Custodian AdministratorVirtus ETF Solutions, LLC AdvisorVirtus ETF Advisers LLC CustodianThe Bank of New York Mellon Corporation DistributorETF Distributors LLC Transfer AgentThe Bank of New York Mellon Corporation TrusteeN/A Lead Market MakerVirtu Financial Miscellaneous Outstanding Shares400,004Beta1.14 Creation Unit50,000 Creation Fee$500.00 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Ad Stansberry ResearchThe Long-Awaited End of America UpdateA 995% Gain Last Time We Shared this "Election Secret" It's a straightforward way to come out on top no matter who wins this November… It's not cryptos, or options, and anyone can do it.Click here to find out for free. Virtus LifeSci Biotech Clinical Trials ETF ExpensesTypeBBCHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.79%0.56%0.54%0.50%0.51%Other Expenses0.00%0.40%0.54%0.64%0.58%Total Expense0.79%0.72%0.70%0.74%0.70%Fee Waiver0.00%-0.53%-0.55%-0.68%-0.57%Net Expense0.79%0.60%0.60%0.58%0.58% Virtus LifeSci Biotech Clinical Trials ETF (BBC) Holdings & ExposureTop 10 BBC HoldingsViking Therapeutics(NASDAQ:VKTX)Holding Weight: 2.85%Alpine Immune Sciences(NASDAQ:ALPN)Holding Weight: 2.79%Vera Therapeutics(NASDAQ:VERA)Holding Weight: 2.59%Avidity Biosciences(NASDAQ:RNA)Holding Weight: 2.44%Bny Mellon Cash Reserve UsdHolding Weight: 2.31%Spyre Therapeutics(NASDAQ:SYRE)Holding Weight: 2.05%Apogee Therapeutics(NASDAQ:APGE)Holding Weight: 1.87%Dyne Therapeutics(NASDAQ:DYN)Holding Weight: 1.76%Sana Biotechnology(NASDAQ:SANA)Holding Weight: 1.75%Cullinan Oncology(NASDAQ:CGEM)Holding Weight: 1.59%BBC Sector ExposureBBC Industry ExposureFull Holdings Details Similar ETFsDirexion Daily Pharmaceutical & Medical Bull 3X SharesNYSEARCA:PILLHarbor Health Care ETFNYSEARCA:MEDIJPMorgan Healthcare Leaders ETFNASDAQ:JDOCHorizon Kinetics Medical ETFNASDAQ:MEDXProShares UltraShort Nasdaq BiotechnologyNASDAQ:BIS BBC ETF - Frequently Asked Questions How have BBC shares performed in 2024? Virtus LifeSci Biotech Clinical Trials ETF's stock was trading at $24.45 at the beginning of the year. Since then, BBC shares have increased by 11.5% and is now trading at $27.27. View the best growth stocks for 2024 here. What does BBC invest in? Virtus LifeSci Biotech Clinical Trials ETF is a equity fund issued by Virtus. BBC focuses on health care investments and follows the LifeSci Biotechnology Clinical Trials Index. The fund's investments total to approximately $10.83 million assets under management. What stocks does Virtus LifeSci Biotech Clinical Trials ETF hold? BBC invests in 106 holdings. Some of the stocks in their portfolio include Viking Therapeutics (VKTX), Alpine Immune Sciences (ALPN), Vera Therapeutics (VERA), Avidity Biosciences (RNA), Spyre Therapeutics (SYRE), Apogee Therapeutics (APGE), Dyne Therapeutics (DYN), Sana Biotechnology (SANA), Cullinan Oncology (CGEM) and Liquidia (LQDA). What is the management fee for Virtus LifeSci Biotech Clinical Trials ETF? Virtus LifeSci Biotech Clinical Trials ETF's management fee is 0.79% and has no other recorded expenses or fee waivers. The net expense ratio for BBC is 0.79%. What other stocks do shareholders of Virtus LifeSci Biotech Clinical Trials ETF own? Based on aggregate information from My MarketBeat watchlists, some companies that other Virtus LifeSci Biotech Clinical Trials ETF investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Intel (INTC), Pfizer (PFE), Simon Property Group (SPG), Cisco Systems (CSCO), Micron Technology (MU), Alibaba Group (BABA) and Johnson & Johnson (JNJ). How do I buy shares of Virtus LifeSci Biotech Clinical Trials ETF? Shares of BBC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEARCA:BBC) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersUrgent Nvidia WarningAltimetryBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingYour bank is lying to you.MyBankTrackerA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsA once-in-a-century investment opportunityStansberry ResearchTrump just won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virtus LifeSci Biotech Clinical Trials ETF Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
